The World Health Organization has approved the first ever malaria drug designed specifically for babies weighing less than five kilograms. The new treatment, called Coartem Baby, fills a dangerous gap that has left the youngest and most vulnerable malaria patients without a proper medical option.
A deadly gap for the smallest patients
Malaria kills more than 600,000 people each year, and children under five account for the vast majority of those deaths. Until now, no antimalarial drug had been tested and approved for infants under five kilograms. Doctors had to crush adult tablets and guess at safe doses. Coartem Baby is a sweet tasting, dispersible tablet that dissolves in milk or water, making it easy for infants to swallow. The drug was developed by Novartis in collaboration with the Medicines for Malaria Venture and other partners.
Why this matters in the countries that need it most
The approval came after clinical trials in three African countries: Benin, Kenya, and Tanzania. These are places where malaria is a daily threat and where babies often die before they reach their first birthday. Local health workers have long pleaded for a drug that fits the smallest bodies. The new treatment is expected to be rolled out across malaria endemic regions starting later this year. The WHO called the approval a major public health milestone.
A long road from lab to village clinic
Coartem Baby is a reformulation of an existing malaria drug, artemether lumefantrine, but tailored for infants. The process took years of research and regulatory work. The drug was granted a positive scientific opinion by the European Medicines Agency under a procedure that allows the WHO to prequalify medicines for global use. That prequalification means the drug can now be purchased by United Nations agencies and other large buyers for distribution in poor countries.
This approval does not end malaria. But it removes a cruel obstacle. For the first time, a baby born with malaria has a medicine made for its own body.
